ImmunoGen Stock Bullish By 9% At Session Start Today

(VIANEWS) – Shares of ImmunoGen (NASDAQ: IMGN) jumped 9.52% to $4.14 at 10:45 EST on Monday, following the last session’s downward trend. NASDAQ is jumping 0.38% to $11,180.71, after two sequential sessions in a row of losses. This seems, up to now, a somewhat bullish trend trading session today.

ImmunoGen’s last close was $3.78, 42.99% under its 52-week high of $6.63.

About ImmunoGen

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

Earnings Per Share

As for profitability, ImmunoGen has a trailing twelve months EPS of $-0.252.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -157.66%.

Sales Growth

ImmunoGen’s sales growth is negative 37.6% for the present quarter and negative 43.7% for the next.

Volume

Today’s last reported volume for ImmunoGen is 957856 which is 73.43% below its average volume of 3605060.

More news about ImmunoGen (IMGN).

Leave a Reply

Your email address will not be published. Required fields are marked *